Activation of Notch 3/C-Myc/chop Axis Regulates Apoptosis and Promotes Sensitivity of Lung Cancer Cells to Mtor Inhibitor Everolimus.

Ting Li,Xiao-Huang Xu,Xia Guo,Tao Yuan,Zheng-Hai Tang,Xiao-Ming Jiang,Yu-Lian Xu,Le-Le Zhang,Xiuping Chen,Hong Zhu,Jia-Jie Shi,Jin-Jian Lu
DOI: https://doi.org/10.1016/j.bcp.2020.113921
IF: 6.1
2020-01-01
Biochemical Pharmacology
Abstract:The mammalian target of rapamycin (mTOR) pathway converges diverse environmental cues to support the lung cancer growth and survival. However, the mTOR-targeted mono-therapy does not achieve expected therapeutic effect. Here, we revealed that fangchinoline (FCL), an active alkaloid that purified from the traditional Chinese medicine Stephania tetrandra S. Moore, enhanced the anti-lung cancer effect of mTOR inhibitor everolimus (EVE). The combination of EVE and FCL was effective to activate Notch 3, and subsequently evoked its downstream target c-MYC. The blockage of Notch 3 signal by the molecular inhibitor of γ-secretase or siRNA of Notch 3 reduced the c-MYC expression and attenuated the combinational efficacy of EVE and FCL on cell apoptosis and proliferation. Moreover, the c-MYC could bind to the C/EBP homologous protein (CHOP) promoter and facilitate CHOP transcription. The conditional genetic deletion of CHOP reduced the apoptosis on lung cancer cells to the same degree as blockage of Notch 3/c-MYC axis, providing further evidence for that the Notch 3/c-MYC axis regulates the transcription of CHOP and finally induces apoptosis upon co-treatment of FCL and EVE in lung cancer cells. Overall, our findings, to the best of our knowledge, firstly link CHOP to Notch 3/c-MYC axis-dependent apoptosis and provide the Notch 3/c-MYC/CHOP activation as a promising strategy for mTOR-targeted combination therapy in lung cancer treatment.
What problem does this paper attempt to address?